Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kemstro vs. conventional baclofen in multiple sclerosis
NCT00139789Phase 3Completed
- Sponsor
- UCB
- Start
- Jan 2005
- Primary completion
- Apr 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of baclofen in multiple sclerosis (MS) (2 arms), sponsored by UCB. Primary endpoint: Subject Preference for Kemstro™ Compared to Conventional Baclofen Tablets. Started Jan 2005; status: completed.
02
Drugs
baclofen
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT00139789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00139789.